PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

US- 2002-0151558 US-2002-0156069

Sheet 1

ESO

ESO

of 19

**Application Number** 10/619,662 Filing Date July 15, 2003 First Named Inventor William Howard Roark Art Unit 1614 **Examiner Name** Unknown Attorney Docket Number PC25132A

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f trown)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
ESO		<sup>US-</sup> 5,082,838	01/21/1992	Naka, et al	
ESO		<sup>US-</sup> 5,817,819	10/06/1998	Furuya, et al	
EŞO		us- 5,948,780	09/07/1999	Peterson Jr., et al	
ESO		<sup>US-</sup> 6,008,243	12/28/1999	Bender, et al	
ESO		<sup>US-</sup> 5,747,486	05/05/1998	Sohda, et al	
ESO		<sup>US-</sup> 5,403,843	04/04/1995	Akimoto, et al	
ESO		US- 5,284,661	02/08/1994	Morimoto, et al	
ESO		<sup>US-</sup> 5,521,181	05/28/1996	Meyer, et al	
ESO		US- 6,166,019	12/26/2000	Meyer, et al	
ESO		<sup>US-</sup> 5,334,596	08/02/1994	Hartman, et al	
ESO		<sup>US-</sup> 4,835,157	05/30/1989	Press, et al	
ESO		<sup>US-</sup> 5,792,767	08/11/1998	Meyer, et al	
ESO		<sup>US-</sup> 5,378,704	01/03/1995	Weller III	
ESO		US- 3,296,070	01/03/1967	Topliss, et al	
ESO		us- 2002-0156061	10/24/2002	Barvian, et al	
ESO		us- 2003-0004172	01/02/2003	Harter, et al	
ESO		<sup>US-</sup> 2002-019377	02/14/2002	Jenkins, et al	
				TA	1

· · · ·		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T-0
		Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)  MM-DD-YYYY		Or Relevant Figures Appear	L	
ESO	•	WO 95/35296	12/28/1995	Takatani, et al	<u> </u>	
ESO	•	WO 99/09485	02/24/2000	McClure, et al		
ESO	,	WO 02/34726	05/02/2001	Noe, et al	*	L
ESO	,	WO 01/12611	02/22/2001	Blagg		L
ESO	8	WO 02/34753	05/02/2002	Bronk, et al		<u></u>
ESO	•	WO 01/05389	01/25/2001	Stallings, et a		

10/17/2002

10/24/2002

Andrianjara, et al

Picard, et al

Date Considered	04/27/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at <a href="https://www.usglo.gov">www.usglo.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^6\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^8\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number PC25132A Sheet 2 of 19

U. S. PATENT DOCUMENTS  Debilioning Date   Name of Patentee or   Pages Columns Lines Where						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (If known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	
ESO		<sup>US-</sup> 2002-0151555	10/17/2002	Barvian, et al		
ESO		<sup>US-</sup> 2002-0161000	10/31/2002	Barvian, et al		
		US-				
	i	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Or Relevant Figures Appear	100		
ESO	•	WO 99/05148	02/04/1999	Collins, et al			
ESO	•	WO 03/049738	06/19/2003	Weithmann,et al			
ESO	•	WO 02/064568	08/22/2002	Barvian, et al			
ESO	,	WO 02/064571	08/22/2002	Barvian, et al			
ESO	•	WO 01/63244 A1	08/30/2001	Chen, et al		L	
ESO		WO 97/07119	02/27/1997	Furuya, et al			

_				
Exami	ner	/Emia Olaan/	Date	04/27/2006
Signat	ure	/Eric Olson/	Considered	01, 11, 1000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usglo.gov">www.usglo.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Transiation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number PC25132A Sheet 3 of 19

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (# known)</sup>			, iguico / poci
		US-	1		
		US-			
		US-			
		US-	1		
		US-			
· <del></del> -		US-			
		US-	1		
		US-	†		
		US-	1		
		US-	1		
		US-			
		US-	†******* <b>*</b>		
		US-	<u> </u>		
	_	US-			
		US-			
		US-			
	1	US-			
		US-			
	†	US-			

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
ESO	•	WO 98/54116	12/03/1998	Castelhano, et al		
ESO	•	WO 96/22991	08/01/1996	Meyer, et al		
ESO		WO 95/28405	10/26/1995	Furuya, et al		
ESO	•	WO 92/20687	11/26/1992	Chakravarty, et al		
ESO	,	WO 00/61583	10/19/2000	Klein, et al		$ldsymbol{f eta}$
ESO	•	WO 00/04027	01/27/2000	Meyer, et al		

1	Examiner	/Eric Olson/	Date Considered	04/27/2006
	Signature	, ====,	1 00.000.00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is a statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown PC25132A Attorney Docket Number Sheet 4 of 19

U. S. PATENT DOCUMENTS  Examiner   Cite   Document Number   Publication Date   Name of Patentee or Pages, Columns, Lines					
examiner Initials*	Cite No.		MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (8 known)</sup>	<u> </u>		rigures Appear
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
<del>~~~~</del>	<del>                                     </del>	US-		<del></del>	
	<b></b>	US-			
		US-	<del>                                     </del>		
		US-		· · · · · · · · · · · · · · · · · · ·	
-		US-		<del></del>	
		US-	+		

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>8</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T.
ESO	•	WO 98/49899	11/12/1998	Atherall, et al		
ESO	•	WO 99/64400	12/16/1999	Salituro, et al		
ESO	1	WO 97/43239	11/20/1997	Van Zandt, et al		
ESO	•	WO 02/064080	08/22/2002	Andrianjara, et al		
ESO		WO 02/064572	08/22/2002	Andrianjara, et al		
ESO	•	WO 00/66584	11/09/2000	Gaudilliere, et al		

٠	Examiner	/Enic Olson/	Date	04/27/2006
	Signature	/Eric Olson/	Considered	04/21/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gog">www.uspto.gog</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Transauor is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

PC25132A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO 10/619.662 **Application Number** Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown

of 19

Sheet 5

Attorney Docket Number

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Number-Kind Code <sup>2 (f known)</sup>			1,941.007.45001			
		US-	1				
	1	US-					
		US-					
	<u> </u>	US-					
	<u> </u>	US-					
		US-					
	<u> </u>	US-					
	<del> </del>	US-					
	<del> </del>	US-					
	<del> </del>	US-					
	<del> </del> -	US-					
	<del>                                     </del>	US-					
<del></del>		US-	1				
		US-	1				
	<u> </u>	US-					
	<del> </del>	US-					
	<b>T</b>	US-					
	<u> </u>	US-					
	<del> </del>	US-					

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document	reign Patent Document Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages					
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>8</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T°				
ESO	•	WO 97/49692 A	12/31/1997	Pirotte, et al						
ESO		WO 98/49146	11/05/1998	Kelley, et al						
ESO		WO 92/20676	11/26/1992	Ito, et al.		L				
ESO	-	EP 0 404 525 B1	05/15/1996	Naka, et al						
ESO		EP 404 525 A		Naka, et al						

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

. PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number PC25132A Sheet 6 of 19

U. S. PATENT DOCUMENTS  Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, Lines, W							
Examiner Initials*	Cite No.1	Number-Kind Code <sup>2 (F known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	<del> </del>	US-	<del> </del>				
		US-			1		
		US-					
		US-					
		US-					
		US-					
		US-					
	<del> </del>	US-					
		US-		· · · · · · · · · · · · · · · · · · ·			
		US-	<u> </u>				
		US-	<u> </u>				
		US-					
		US-					
		US-					
		US-					
		US-		<del></del>			
		US-					
		US-			1		
		US-	-				
			1 1				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Π			
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Te			
ESO	ď	EP 0935963	08/18/1999	McClure, et al					
ESO	٠	EP 1138680	10/04/2001	Noe					
ESO		EP 0418797	03/27/1991	Baader, et al					
ESO		EP 0463592	01/02/1992	Baader, et al					
ESO	4	EP 0 915 093 A	05/12/1999	Okamura, et al					
ESO		EP 0 530 537 B1	01/08/1997	Akimoto, et al					

Examiner Signature /Eric Olson/	Date Considered 04/27/2006	
---------------------------------	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown Attorney Docket Number PC25132A of 19 Sheet 7

Evaminer	Examiner Cite Document Number Publication Date Name of Patentee or Pages, Columns, L						
Initials*	Cite No.1	Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US-					
		US-			_		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		·			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			*		
		US-	1 1				
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>8</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	To			
ESO	-	EP 0 443 568 A1	08/28/1991	Morimoto, et al					
ESO	•	EP 0 443 568 B1	06/12/1996	Morimoto, et al	11				
ESO	7	EP 0 492 316 A1	07/01/1992	Akimoto, et al					
ESO	1	EP 0 502 725 A2	09/09/1992						
ESO	,	EP 0 530 537 A1	03/10/1993	Akimoto, et al					
ESO	•	EP 0 416 740 A2	03/13/1991	Smith, et al					

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional), 'See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8

of 19

Application Number 10/619.662 Filing Date July 15, 2003 First Named Inventor William Howard Roark Art Unit 1614 Examiner Name Unknown PC25132A Attorney Docket Number

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		US-						
		US-		<del></del>	<del></del>			
		US-	l l					
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-		-				
		US-						
		US-						
		US-						
		U\$-						
		US-						
		US-						
		UŞ-						
		US-						

	FOREIGN PATENT DOCUMENTS								
Examiner Initiats*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Π			
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear				
ESO	•	EP 0 297 661 B1	09/16/1992	Janssens, et al					
ESO	•	EP 0 438 261 A2	07/24/1991	Akimoto, et al					
ESO	•	EP 0 297 661 A1	01/04/1989	Janssens, et al					
ESO		EP 0 282 133 B1	09/14/1988	Janssens, et al					
ESO		EP 260 057 A2	03/16/1988	Schmalzl, et al					
ESO		EP 0 463 592	01/02/1992	Baader, et al					

miner nature	/Eric Olson/		Date Considered	04/27/2006
		•		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown PC25132A Sheet 9 of 19 Attorney Docket Number

Examiner	Cite	Document Number	U. S. PATENT D  Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code <sup>2</sup> (# known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	<del> </del>	US-	<del></del>		<del></del>
		03-			
		US-			
_		US-			
	l	US-			
		US-			
		US-			
	<del> </del>	US-	<del> </del>		

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Ι.
	<u> </u>	Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	To
ESO	1	GB 2 097 396 A	11/03/1982	Seivaku, et al		L
ESO	1 .	DE 41 37 437 A1	05/19/1993	Furrer, et al		
ESO		JP 5193260	03/08/1993			
ESO	1	DE 2441959	03/13/1975	Egli, et al.		
ESO	,	FR 4279M	08/16/1966	Vernin, et al	•	
ESO	•	JP 08 151380 A	06/11/1996			

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is a statched.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

William Howard Roark

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003

First Named Inventor

## INFORMATION DISCLOSURE

STATEMENT BY APPLICANT	Art Unit	1614
(Use as many sheets as necessary)	Examiner Name	Unknown
- 10 - 10	Attorney Docket Number	PC25132A

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
		us-			
		US-			
	<u> </u>	US			
	<del> </del>	US-			
	<b> </b>	US-			
		US-			-
	<b> </b>	US-	<del> </del>		
		US-		<del> </del>	
	<del>                                     </del>	US-			
	<del>                                     </del>	US-			
<del></del>	<del>                                     </del>	US- ·	- <del> </del>		
		US-			
	<del>                                     </del>	US-			
		US-			
	<b> </b>	US-			
	T	US-			
		US-			
	<b>†</b>	US-	<del>                                     </del>		
		US-	<del>                                     </del>		

		FORE	IGN PATENT DOCU	JMENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
ESO		WO 02/064599	08/22/2002	Andrianjara, et al		
ESO	,	WO 02/064547	02/22/2002	Barvian, et al		L
ESO		WO 02/064598	08/22/2002	Harter, et al		
ESO	′	WO 02/064572	02/22/2002	Andrianjara, et al		
ESO	4	WO 02/064595	08/22/2002	Andrianjara, et al		

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/619,662 Filing Date July 15, 2003 INFORMATION DISCLOSURE First Named Inventor William Howard Roark STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Unknown PC25132A

Sheet 11

of 19

Attorney Docket Number

Examiner	Cite No.1	Document Number	U. S. PATENT D	. Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
		US-			
•		US-			
		US-	1		
		US-			
		US-			
		US-			
		US-	T		
		US-			
-	<del>                                     </del>	US-	<del> </del>		
		US-		· · · · · · · · · · · · · · · · · · ·	
	<del> </del>	US-			·
		US-			
		US-			
·· · · · · · · · · · · · · · · · · · ·		US-			
		US-	<del>                                     </del>		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Oate	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
ESO	.4	WO 02/064578	08/22/2002	Picard, et al		L
						L
						┡
				<u> </u>		┢
						-

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO		ct of 1995, no persons ar	Complete if Known		
Cassino	10 101111 144011 10		•	Application Number	10/619,662	
INF	ORMATION	I DIS	CLOSURE	Filing Date	July 15, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	William Howard Roark	
	(llee ee meeu che		occessed	Art Unit	1614	
	(Use as many sheets as necessary)			Examiner Name	Unknown	
Sheet	12	of	19	Attorney Docket Number	PC25132A	

	NON PATENT LITERATURE D	OCUMENTS
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), ti the item (book, magazine, journal, serial, symposium, number(s), publisher, city and/or co	catalog, etc.), date, page(s), volume-issue   T <sup>2</sup>
ESO	Montana, et al, "The design of selective non-sub- inhibitors", Current Opinion in Drug Discovery & I	
ESO	Clark, et al, "Matrix metalloproteinase inhib Current Opinion in Drug Discovery & Deve	oitors in the treatment of arthritis", lopment, 2000; 2(1); pp 16-25
ESO	Chen, et al, "Structure-Based Design of a Novel, Pote Utilizing NMR Spectroscopy and Computer-Aided Mol 2000, 122; pp 9648-9654	ent, and Selective Inhibitor for MMP-13 lecular Design", J. Am. Chem. Soc.,
ESO	Derwent Abstract 96-068630/07, "New fus inhibitory activity of adhesion molecule ex	
ESO	Derwent Abstract 93-168431/21, "New The for treating anteriosclerosis"	niazolo-pyrimidine disone derivs.
ESO	Derwent Abstract 91-001547/01, "New sulphur-Contg. and interleukin inhibitors for treatment and prevention of diseases, etc.",	fused pyrimidine cpds are endothelin of myocardial infarction, auto:immune
ESO	Derwent Abstract, 93271 E/44, "Cyclised programmer or ally administered antitumour agent	pro-form of 5-fluoro-uracil derivs. s without side effects of parent"
ESO	Kaul, et al, "2-14C-1-Allyl-3,5-diethyl-6-chlorouracil II: I Sulfur-Free and Three Minor Sulfur-Containing Metabo Biotransformation", Journal of Pharmaceutical Science	olites and Mechanism of
ESO	Kaul, et al, "Structure of a novel sulphur-conta (1-allyl1-3,5-diethyl-6-chlorouracil)", Xenobiotic	nining metabolite of Acluracil ca, 1982, Vol. 12, No. 8; pp 495-498
ESO	Kaul, et al, "Identfizierung eines dritten S-haltigen Metabo Bildungsmechanismus der SCH - Metaboliten", Arzneim.	oliten von 1-Allyl-3,4-diethyl-6-chloruracil und Forsch./Drug Res., 982; 32(I)(6); pp 610-612

		<del></del>	<del>,</del>
Examiner	/Eric Olson/	Date	04/27/2006
Signature	/ Elic Olson/	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

PC25132A

Under the Paperwork Reduction Act of 1995, no persons ar		on of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known
Substitute for form 14437 10	Application Number	10/619,662
NFORMATION DISCLOSURE	Filing Date	July 15, 2003
STATEMENT BY APPLICANT	First Named Inventor	William Howard Roark
##	Art Unit	1614
(Use as many sheets as necessary)	Examiner Name	Unknown

**Attorney Docket Number** 

Sheet

13

19

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ESO	÷	Brown, et al, "The Synthesis of Some 1-Substituted Cytosine and Uracil" Derivatives", J. Chem. Soc., 1972; pp 2385-2391	
ESO		Peccrari, et al, "Synthesis and Biological activity of Pyrimido [2,1-b] [1,3] Thiazine, [1,3]Thiazino[3,2-a]Purine and [1,2,3]Triazolo[4,5-d][1,3]Thiazino [3,2-a]Pyrimidine Derivatives and thiazole Analogues (*)", IL Farmaco, 46 (7,8), 1991; pp 899-911	
ESO		De Melo, et al, "5-fluoro (3H) pyrimidine-4-ones; syntehse, reactivite et proprietes pharmacologiques", Ann. Pharmaceutiques francaises, 1992, 50, n1; pp 39-51	
ESO		Faskhutdinow, et al, Kim. Farm. Zh. 1988; 22(5); pp 557	
ESO		Tozkoparan, et al, "Condensed Heterocyclic Compounds: Synthesis and Antiinflammatory Activity of Novel Thiazolo[3,2-a]pyrimidines", Arch. Pharm. Pharm. Med. Chem. 331 (Weinheim, Germany): 1998; pp 201-206	
ESO		Chem. Abstr. 1992; 117; pp 143023e	
ESO		Chem. Abstr. 1988; 109; pp 162901r	
ESO		Boger, et al, "Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin. alpha. V. beta 3", Journal of the American Chemical Society 2001; 123: pp 1280-1288	
ESO		Silletti, et al, "Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo", Proceeding of the National Academy of Sciences of the United States of America, 2001; 98(1); pp 119-124	
ESO		Milton, et al, "Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2", Bioorganic & Medicinal Chemistry Letters, Oxford, GB 1998; 8: pp 2623-2628	

Examiner		•	Date	04/27/2006
Signature	/Eric Olson/		Considered	04/2//2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO		Complete if Known		
Cubanc	10 10 10 11 14 37 10	•		Application Number	10/619,662
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 15, 2003
STA	TEMENT	Application Number 10/6 ATION DISCLOSURE ENT BY APPLICANT  S many sheets as necessary)  Application Number 10/6 Filling Date July First Named Inventor Willia Art Unit 1614 Examiner Name Unkr	William Howard Roark		
	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1614	
	(USB as many s	กษยเร 83 ก	ecessary)	Examiner Name	Unknown
Sheet	14	of	19	Attorney Docket Number	PC25132A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ESO		Hirota, et al, "Synthesis of 6-Substituted Thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones", J. Heterocycl. Chem., Vol 12, 1974; pp 717-721	
ESO		Rajappa, et al, "Synthesis of Thiophenes: Part III* - Further Variations in the Substitution Pattern", Indian J. Chem., Vol 12, 1974; pp 1-3	
ESO		HCAPLUS Abstract 1998: 542760; "Preparation of bicyclic-substituted hexahydrobenz [e] isoindoles as a1 adrenergic antagonists"	
ESO		HCAPLUS Abstract 1990: 514925; "Pyrimidines. 65. Synthesis of 6-substituted thieno [2,3-d] pyrimidine-2 4(1H,3H) - diones"	
ESO		Derwent Abstract 2000-687031/67, "New Xanthine derivatives are inhibitors of cellular processes mediated by interleukin-12 for treating inflammatory responses e.g. chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis and asthma (Eng)"	
ESO		Derwent Abstract 92-415690/50, "New Pyrimidinone derivs are angiotensin II antagonists for treating hypertension, congestive heart failure, renal failure, Alzheimer's diesease, amnesia, schizophrenia, etc. (Eng)"	
ESO		Derwent Abstract 92-302020/37, "New fused pyrimidinone derivs are antiotensin II antagonists to treat hypertension, congestive heart failure, Alzheimer's disease, amnesia, anxiety, schizophrenia, etc. (Eng)"	
ESO		Derwent Abstract 91-254180/35, "New angiotensin-II antagonising fused thiphene derivatives - used for treating hypertension and circulatory diseases including heart diseases and stroke"	
ESO		Derwent Abstract 89-192246/26, "New 3-piperidinyl:alkyl-thieno: or furo pyrimidine-2,4-di:one cpds usefule as seratonin antagonists and alpha adrenergic blockers"	
ESO		Derwent Abstract 2000-195023/17, "New ipiperazinyl pyrimidine dione derivatives used as selective alpha-ID adrenoceptor antagonists for treating benign prostatic hyperplasia, hypertension, detrusor instability and incontenence (Eng)"	

Examiner   /Eric Olson/	Date Considered	04/27/2006
-------------------------	--------------------	------------

<sup>\*</sup>EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PT0	)			Complete if Known
Jupsiilu	te to to the 1443/FTC	•	•	Application Number	10/619,662
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 15, 2003
STA	STATEMENT BY APPLICANT			First Named Inventor	William Howard Roark
	NFORMATION DISCLOSUR STATEMENT BY APPLICAN (Use as many sheets as necessary)		Art Unit	1614	
	(Use as many a	ineets as n	iecessary)	Examiner Name	Unknown
Sheet	15	of	19	Attorney Docket Number	PC25132A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ESO		Derwent Abstract 2001-158207/16, "New piperazinyl pyrimidine dione derivatives are selective alpha-ID adrenoceptor antagonists used for treatment of e.g. hypertension"	
ESO		Derwent Abstract 96-362624/36, "New Bi:cyclic substd. hexa:hydro-benz-isoindole derivs are alpha-1 adrenergic antagonists, used in treatment of benign prostatic hyperplasia (Eng)"	
ESO		Derwent Abstract 89-008928/02, "New bi:cyclic heterocycle substd. hexa-hydro-1H-azepine-and pyrrolidine cpds., have anti-histaminic properties, for treatment of e.g. allergic rhinitis, allergic asthma, etc."	
ESO		Derwent Abstract 88-258874/37, "New 1-alkyl substd. benzimidazole derivs having anti-histaminic activity and used for treating allergic diseases such as allergic asthma"	
ESO		Derwent Abstract 91-216939/30, "New condensed heterocyclic glutemic acid dervis., - active against enzyme using folic acid and antitumour agents for treating e.g. leukemia"	
ESO		Derwent Abstract 99-080786/07, "New thiophene-and pyrrole-based hetero-aromatic compounds - are ant(agonists of cell surface receptors, useful e.g. for inhibiting unwanted cell growth e.g. due to cancer (Eng)"	
ESO		Derwent Abstract 97-165234/15, "New thieno-pyrimidine derivs. are endothelin antagonists - useful for treating e.g. acute renal failure, cardiac infarction, liver insufficiency, organ hypo-function and vasoconstriction (Eng)"	
ESO		Derwent Abstract 96-384384/38, "New 2,4(1H,3H)-di:oxo-5-aminoalkyl)thieno(2,3-d)-pyrimidine derivs are gonadotropin-releasing hormone antagonistic agents useful in prevention and treatment of sex hormone dependent diseases (Eng)"	
ESO		Derwent Abstract 95-382760/49, "Fused bicyclics as gonadotropin releasing hormone antagonists - used for treating hormone related cancers, benign prostatic hypertrophy, acne vulgaris, etc. (Eng)"	
ESO		Derwent Abstract 93-299636/38, "New condensed heterocyclic oligo-glutamate derivs used as water soluble antitumour agent and have bood storage stability in cells"	

- 1	Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ed to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitu	18 107 10fm 1449/F	710		Application Number	10/619,662		
INF	ORMATI	ON DIS	CLOSURE	Filing Date	July 15, 2003		
STA	TATEMENT BY APPLICAN	PPLICANT	First Named Inventor	William Howard Roark			
		MATION DISCLOSURE MENT BY APPLICANT  se as many sheets as necessary)	Art Unit	1614			
	(Use as man	y sheets as n	ecessary)	Examiner Name	Unknown		
Sheet	16	of	19	Attorney Docket Number	PC25132A .		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ESO		Derwent Abstract 93-078155/10, "New antitumour condensed pyrimidine derivs for treating chorlocarcinoma, leukemia, breast adenocarcinoma, squamous cells carcinoma, lung cancer, lympho sarcoma, etc. and also rheumatism (Eng)"	
ESO		Derwent Abstract 92-218561/27, "Antitumoural condensed heterocyclic oligo:glutamate derivs for treating leukemia, squamous cell carcinoma, lymphatic sarcoma, small cell cancer of the lung etc. (Eng)"	
ESO		Derwent Abstract 96-267825/27, "New hexa:hydro benz(e)isoindole cpds are useful in treatment of benign prostatic hpyerplasia (Eng)"	
ESO		Derwent Abstract 94-248420/30, "Furano- and thieno- (3,2-c)piperidone carboxamido-acids - are fibrinogen receptor antagonists, inhibit blood platelet aggretation, used in thrombi and emboli treatment"	
ESO		Derwent Abstract 91-075241/11, "Heterocyclic peptide derivs. useful as renin inhibitors - in the treatment of hypertension, congestive heart failure, retro-viral diseases and central nervous system disorders"	
ESO		HCAPLUS Abstract 1996:580284: "Preparation of heterocyclyl-substituted benz[3]isoindoles as x1 adrenergic antagonists"	
ESO		Liverton, et al, "Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists", Bioorganic & Medicinal Chemistry Letters, 1998; 8(5); pp 483-486	
ESO		Ogawa, et al, "Studies on positive inotropic agents V", Chem Pharm Bull, 1988; 36(6); pp 2253-2258	
ESO		Chemical Abstract CHEMCATS: AN 2001: 142935 for Order no. A1240/0056923 "Screening Collection", Zelinsky Institute of Organic Chemistry, Russia, 2000	
ESO		Chemical Abstract CHEMCATS: AN 2001:2519212, 2001:2519208, and 2001:2519206 for Order no.s CHS 1938401, CHS 1938397, and CHS 1938395, respectively, "Chemstar Product List", Chemstar Ltd. Russia, 2001	

Examiner		Date	04/27/2006
LXamilio	/Eric Olson/		04/4//4000
Signature	· / HITC OIBOH/	Considered	· · ·
Signature			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reterence considered, whether or not clauton is in contiminate with mix or manufacture of the considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to ptace a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number.

Under the Faperwork Keedecler Act of Young to parents				Complete if Known		
Substitu	te for form 1449/PTC	,		Application Number	10/619,662	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 15, 2003	
STATEMENT BY APPLICANT				First Named Inventor	William Howard Roark	
				Art Unit	1614	
(Use as many sheets as necessary)				Examiner Name	Unknown	
Sheet	17	of	19	Attorney Docket Number	PC25132A	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	itials* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T²
ESO		Chemical Abstract: CHEMCATS: AN 2001:2624610, 2001:2320591, 2002:928648, 2002:925092, 2002:926648, and 2002:927094 for Order nos. STOCKIN-22756, A1336/0060317, STOCKIS-85693, STOCKIS-77305, STOCKIS-81043, and STOCKIS-82046, respectively, "Ambinter:Exploratory Library", Ambinter, Paris, 2002	
ESO		Chemical Abstract CHEMCATS: AN 2001:1621701, 2001:1621700, 2001:1433023, 2001:1433022, and 2001:1433020 for Order nos. Z-007159, Z-007158, C-055659, C-055658, and C-055656, respectively, "Scientific Exchange Product List", Scientific Exchange, Inc., USA, 2001	
ESO		Chemical Abstract: Abstract No. 54:2375e for Nesterov, et al, Compound: Pyrimido '5,4-d pyrimidine-2, 4(1H, 3H)-dione, 6-(benzylthio)-, RN 00382-60-3, USA 1960	
ESO		Chemical Abstract CAPLUS: Abstract No. 128:243870 (1998:224550) for Murata, et al, "Regioselective synthesis of 6-substituted lumazines by using highly reactive lumazine 6-triflate", Germany 1997; 17-22	
ESO		Chemical Abstract CAPLUS: Abstract No. 128:243871 (19898:224554) for Kim, et al, "Side chain reactions of 6-acetyl-1,3,7-trimethyllumazine", Germany 1997; 41-44	
ESO		Chemical Abstract CAPLUS: Abstract No. 126:212115 (1997:100238) for Abou-Hadeed, et al, "Pteridines CVIII Reactions of 6,7-dichloro-1,2-dimethyllumazine with sulfur nucleophiles", Pteridines 1996; 7(4); 113-122	
ESO		Chemical Abstract CAPLUS: Abstract No. 107:58977 (1987:458977) for Sladowska, et al, "Synthesis and properties of amides of 1-benzyl-3-methyl-an 1-butyl-3-phenyl-7-methyl-4-oxo-2-thioxo (2,4-dioxo)-1,2,3,4-terrahydropyrido '2,3-dipyrimidine-6-carboxylic acids", Farmaco, Ed.Sci. 1986; 41(12); 954-963	
ESO		Chemical Abstract CAPLUS: Abstract No. 87:152121 (1977:552121) for Lespagnol, et al, "Study on antifolic agesnt. 1. Derivatives of 4-nitrobenzene-1,3-dicarboxylic acid", Bull. Soc. Pharm. Lille 1977; 33(1); 67-77	
ESO		Chemical Abstract CAPLUS: Abstract No. 101:16805 (1984: 416805) for Ghose, et al, "A general distance-geometry three-dimensional receptor model for diverse dihydrofolate reductase Inhibitors", J. Med. Chem. 1984; 27(7); 901-914	
ESO		Reiter, et al, "Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket", Bioorganic & Medicinal Chemistry Letters, 1999; 9; 127-132	

Examiner	/Eric Olson/	Date	04/27/2006
Signature	, ==== 0===,	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information unless it contains a valid OMB control number.

Cubation	te for form 1449/PT	^		Complete if Known		
Substitui	ie iorioim 1443/Pi	U		Application Number	10/619,662	
INFO	ORMATIC	N DIS	CLOSURE	Filing Date	July 15, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	William Howard Roark	
				Art Unit	1614	
(Use as many sheets as necessary)			ecessary)	Examiner Name	Unknown	
Sheet	18	of	19	Attorney Docket Number	PC25132A	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T²
ESO	ESO  Derwent Abstract 95-051281/07, "New benzo- and pyrido- 1,2,4-thiadiazine dioxide derivs are angiotension II inhibitors, use in treatment of hypertension and congestive heart failure."		
ESO	•	Chemical Abstracts, Vol 125, No. 13, 1996, Abstract No. 167964d; XP002198554	
ESO	•	Database Crossfire Bulletin, Online, Database accession no. 786662; XP002198556	
ESO		Shkurko, et al, Khim. Geterotsikl. Soedin, 1977; 6; pp 821-824	
ESO	/	Database Crossfire Bulletin, 'Online, Database accession no. 7297869; XP002198557	
ESO		Yamamoto, et al, "Direct Introduction of ACYL and Ethoxycarbonyl, Groups Into Pyrimidine Through the Trimethyl-Stannyl Derivatives" Heterocycles, 1995; 41(6); pp 1275-1290	
ESO		Database Crossfire Bulletin, 'Online, Database accession no. 139954; XP002198558	
ESO		Hunt, et al., "Pyrimidines. Part X. Pyrimidine, 4:6-Dimethylpyrimidine, and their 1-Oxides," J. Chem. Soc., 1959; pp 525-530	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPP 609. Draw tine through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/619,662	
INF	ORMATION	DIS	CLOSURE	Filing Date	July 15, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	William Howard Roark	
	///co oo many abo	oto		Art Unit	1614	
(Use as many sheets as necessary)				Examiner Name	Unknown	
Sheet	19	of	19	Attorney Docket Number	PC25132A	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T <sup>2</sup>
ESO		Database Crossfire Bulletin, 'Online, Database accession no. 791572; XP002198559	
ESO		Sakasi, et al, "Studies in Pyrimidine Derivatives. XVII. Synthesis of Pyrimidine-4-Carboxyl Heterocycles", 1979; 13; pp 235-236	
ESO		Chemical Abstracts, Vol. 79, No. 11, Abstract No. 66394; XP002198555	
ESO		Chemical Abstracts CA Online! CASREACT AN 105:226286 of Vinsova, J. et al, "Antituberculotics XXXVII. Preparation of the functional derivatives of 6-methyl-2-pyridinecarboxylic acid substituted in position 4 and its 1-oxides" CESK. FARM. 1985;34(10:430-436 (XP002202692)	
ESO		Hanauske-Abel HM. et al, "Pyrroloquinoline quinone and molecules mimicking its functional domains. Modulators of connective tissue formation?" Federation of European Biochemical Studies Letters 1987, 214(2); 236-243 (XP002202687)	
ESO		Rateb, et al, "Synthesis of heterocylic compds. from delta-unsaturated 1,3-diketo-esters Part III. ethyl 3-cyano-6-styryl-2-pyridone-4-carboxylates and their degradation products", Journal of the Chemical Society 1960, 1430-1434 (XP002202688)	
ESO		Chemical Abstracts: AN 61:6987c "Preparation of pyridinedicarboxaldehydes" (XP002202689)	
ESO		Chemical Abstracts: AN 64:6607g "Compounds with potential antitubercular activity" (XP002202690)	
ESO		Chemical Abstracts: AN 55:10440b "Solubilizing agents. V. Pyridinecarboxamides" (XP002202691)	
550		Pyridinecarboxamides" (XP002202691)	

Examiner Signature	/Eric Olson/	Date Considered	04/27/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.